The increased cellular uptake and biliary excretion of curcumin by quercetin: A possible role of albumin binding interaction

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1452-1455

  Kim, Han Gyul ^a   Lee, Joo Hyun ^a   Lee, Seung Jae ^a   Oh, Ju Hee ^a   Shin, Eunji ^a   Jang, Young Pyo ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CUCURMIN SULFATE; CURCUMIN; DRUG METABOLITE; QUERCETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CARCINOMA CELL; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALBUMINS; ANIMALS; CELL LINE, TUMOR; CURCUMIN; HUMANS; MALE; PROTEIN BINDING; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84863915515     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044123     Document Type: Article

References (38)

1. Aggarwal BB, Sundaram C, Malani N, and Ichikawa H (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1-75.
2. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, and Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582.
3. Barik A, Priyadarsini KI, and Mohan H (2003) Photophysical studies on binding of curcumin to bovine serum albumins. Photochem Photobiol 77:597-603.
4. Benet LZ and Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115-121.
5. Boots AW, Haenen GR, and Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585:325-337.
6. Boulton DW, Walle UK, and Walle T (1998) Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 50:243-249.
7. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, and Giardiello FM (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035-1038.
8. Cunderlíková B, Moan J, and Sjaastad I (2005) pH dependent uptake of porphyrin-type photosensitizers by solid tumor cells in vitro is not induced by modification of transmembrane potential. Cancer Lett 222:39-47.
9. Di Bari L, Ripoli S, Pradhan S, and Salvadori P (2010) Interactions between quercetin and warfarin for albumin binding: a new eye on food/drug interference. Chirality 22:593-596.
10. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, et al. (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625-632.
11. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel Dekker, Inc., New York.
12. Hsu CH and Cheng AL (2007) Clinical studies with curcumin. Adv Exp Med Biol 595:471-480.
13. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61:1058-1064.
14. Janisch KM, Williamson G, Needs P, and Plumb GW (2004) Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic Res 38:877-884.
15. Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB, and Gescher AJ (2004) Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Br J Cancer 91:1213-1219.
16. Li X and Choi JS (2009) Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29:1411-1415.
17. Luo SM, Tan WM, Deng WX, Zhuang SM, and Luo JW (2005) Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 11:4272-4276.
18. Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, and Samuel J (2007) High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomed Chromatogr 21:546-552.
19. Mahady GB, Pendland SL, Yun G, and Lu ZZ (2002) Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 22:4179-4181.
20. Mandeville JS, Froehlich E, and Tajmir-Riahi HA (2009) Study of curcumin and genistein interactions with human serum albumin. J Pharm Biomed Anal 49:468-474.
21. Morand C, Crespy V, Manach C, Besson C, Demigné C, and Rémésy C (1998) Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 275:R212-R219.
22. Noguchi P, Wallace R, Johnson J, Earley EM, O'Brien S, Ferrone S, Pellegrino MA, Milstien J, Needy C, Browne W, et al. (1979) Characterization of the WIDR: a human colon carcinoma cell line. In Vitro 15:401-408.
23. Oh JH, Park SE, Shim CK, and Lee YJ (2009) Biliary clearance of bromosulfophthalein in anesthetized and freely moving conscious rat. Biopharm Drug Dispos 30:94-98.
24. Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, and Poelstra K (2009) Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia 11:1348-1358.
25. Prakobwong S, Khoontawad J, Yongvanit P, Pairojkul C, Hiraku Y, Sithithaworn P, Pinlaor P, Aggarwal BB, and Pinlaor S (2011) Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer 129:88-100.
26. Pulla Reddy AC, Sudharshan E, Appu Rao AG, and Lokesh BR (1999) Interaction of curcumin with human serum albumin-a spectroscopic study. Lipids 34:1025-1029.
27. Rolan PE (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37:125-128.
28. Sansom LN and Evans AM (1995) What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12:227-233.
29. Sharma RA, Gescher AJ, and Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41:1955-1968.
30. Shehzad A, Khan S, Shehzad O, and Lee YS (2010) Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today (Barc) 46:523-532.
31. Shitara Y, Sato H, and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
32. Smith DA, Di L, and Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929-939.
33. Suphim B, Prawan A, Kukongviriyapan U, Kongpetch S, Buranrat B, and Kukongviriyapan V (2010) Redox modulation and human bile duct cancer inhibition by curcumin. Food Chem Toxicol 48:2265-2272.
34. Wang HK (2000) The therapeutic potential of flavonoids. Expert Opin Investig Drugs 9:2103-2119.
35. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, Lee PW, Giacomantonio CA, and Hoskin DW (2010) Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett 297:1-8.
36. Wilson TD (1990) Liquid chromatographic methods validation for pharmaceutical products. J Pharm Biomed Anal 8:389-400.
37. Zhang DM, He ZW, Liu XD, Li Y, Xie L, Wang GJ, and Liu L (2007) In-vivo and in-vitro studies on the effect of Huang-Lian-Jie-Du-Tang on nimodipine transport across rat bloodbrain barrier. J Pharm Pharmacol 59:1733-1738.
38. Zhou S, Lim LY, and Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104.